Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1221 results about "Pharmacokinetics" patented technology

Pharmacokinetics (from Ancient Greek pharmakon "drug" and kinetikos "moving, putting in motion"; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to determine the fate of substances administered to a living organism. The substances of interest include any chemical xenobiotic such as: pharmaceutical drugs, pesticides, food additives, cosmetics, etc. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is the study of how an organism affects a drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising a tolfenamic acid

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Intelligent prediction model and method for postoperative complications of anesthetized patient

The invention relates to the technical field of medical information, in particular to an intelligent prediction model and method for postoperative complications of anesthetized patients, and the method comprises the steps: collecting preoperative to postoperative complete-cycle clinical data of a patient through a medical data interface; analyzing operation codes to generate risk features, extracting vital sign dynamic features, and establishing a complication probability mapping relation through a multi-modal fusion network; combining the complication probability and pharmacokinetic parameters to construct an optimization model, and solving an individualized anesthetic dosage interval by using a gradient descent algorithm; vital signs are dynamically monitored in the operation, a dose re-optimization mechanism is triggered, the infusion rate is adjusted, and a closed-loop control link is formed; and generating a visual decision report. According to the method, through deep integration of complete-cycle clinical data and multi-modal feature modeling, preoperative physiological parameters, operation coding semantic information and intraoperative vital sign dynamic modes are subjected to fusion analysis, a nonlinear mapping relation between dosage and complication probability is constructed, and the risk prediction precision and individualized adaptability are remarkably improved.
Owner:BEIJING ANZHEN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Quinazoline compound, and pharmaceutical composition thereof and use thereof

Disclosed in the present invention are a quinazoline compound, and a pharmaceutical composition thereof and the use thereof. Provided in the present invention is a compound as represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compounds of the present invention have a good degradation effect on the KRAS protein with a G12D mutation, have a good inhibitory activity against the proliferation of tumor cells with a KRAS G12D mutation, and exhibit good pharmacokinetic properties.
Owner:HANGZHOU POLYMED BIOPHARMACEUTICALS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Optimized binuclease fusions and methods

The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
Owner:RESOLVE THERAPEUTICS LLC

Tetrahydrofuramide sodium channel regulator and application thereof in medicine

The invention provides a substituted tetrahydrofuran carboxamide derivative, salt or stereochemical isomer, a pharmaceutical composition containing the substituted tetrahydrofuran carboxamide derivative, application of the substituted tetrahydrofuran carboxamide derivative as a Nav inhibitor and application of the substituted tetrahydrofuran carboxamide derivative in preparation of drugs for treating and / or relieving pain and pain related diseases. The compound provided by the invention has the advantages of high metabolic stability, high oral absorption, better bioavailability, better activity, higher selectivity, better pharmacokinetic property, quicker effect, low side effect on central nervous system and the like.
Owner:ANDIKANG (WUXI) BIOLOGICAL TECH CO LTD

Compound as LPAR1 antagonist, pharmaceutical composition thereof and use thereof

A compound as an LPAR1 antagonist, a pharmaceutical composition thereof and a use thereof. A compound represented by formula (I), as well as a racemate, stereoisomer, tautomer, nitrogen oxide, or pharmaceutically acceptable salt thereof. The compound of the LPAR1 antagonist has a good inhibitory effect on LPAR1, has excellent pharmacokinetic properties, and has good druggability.
Owner:WUHAN LL SCI & TECH DEV CO LTD

Gemigliptin oxalate as well as crystal form, preparation method and application thereof

The invention discloses a gemigliptin oxalate and a crystal form, a preparation method and application thereof, relates to the technical field of medicinal chemistry, and provides the crystal form of the gemigliptin oxalate, the crystal form is not reported in the prior art, and animal experiments show that compared with gemigliptin tartrate and gemigliptin hydrochloride, the crystal form of the gemigliptin oxalate has the advantages that the crystal form of the gemigliptin oxalate is more stable. The gemigliptin oxalate prepared by the invention has better pharmacokinetic performance, and lays a foundation for development and application of a new dosage form of gemigliptin; the invention further provides a simple and efficient gemigliptin salt forming process, compared with a method for removing an amino protecting group through acid treatment, the salt forming process provided by the invention does not need to add alkali to dissociate the amino group, impurity generation caused by strong acid or strong alkali is avoided, and the prepared gemigliptin oxalate is high in purity.
Owner:ANHUI HERYI CHEM

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Multi-target drug screening and optimizing method based on machine learning

The invention belongs to the technical field of drug screening, and provides a multi-target drug screening and optimizing method based on machine learning, which comprises the following steps: S1, carrying out feature screening on compound molecular descriptors by utilizing a machine learning algorithm, and determining the molecular descriptor which has the most significant influence on biological activity; s2, constructing a quantitative structure-activity relation model, and predicting the biological activity of the compound; s3, based on a multi-objective optimization algorithm, combining absorption, distribution, metabolism, excretion and toxicity properties of the compound; according to the method, feature screening is carried out on compound molecule descriptors by utilizing a machine learning algorithm, a QSAR model is constructed to predict the biological activity, ADMET property classification prediction is combined, the biological activity, ADMET properties and pharmacokinetic characteristics of drugs are comprehensively considered, and the accuracy and accuracy of drug activity prediction are improved. The method can efficiently and accurately screen and optimize drug candidate compounds with potential drug effects and good pharmacokinetic characteristics, so that the success rate of drug research and development is increased, and the research and development cost and time are reduced.
Owner:XIAN EURASIA UNIVERSITY

Prodrugs of MDMA, MDA, and derivatives thereof

The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
Owner:EMPATHBIO INC

Deep regression estimation of arterial input function for dynamic pet

According to various embodiments, machine learning techniques for determining a pharmacokinetic parameter of a radiotracer in a patient are presented. The techniques include: obtaining a time sequence of positron emission tomography (PET) scans of a target tissue of the patient, where the time sequence of PET scans includes images of a radiotracer in the target tissue; providing the time series of the PET scans to a first neural network system, which provides features extracted from the time series of the PET scans; providing the features extracted from the time series of the PET scans to a second neural network system, which provides an estimated arterial input function; modeling the pharmacokinetic parameter of the radiotracer based on the estimated arterial input function and the time sequence of PET scans; and outputting an estimate of the pharmacokinetic parameter of the radiotracer based on the modeling.
Owner:JOHNS HOPKINS UNIVERSITY

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Crystal form of neuroactive steroid derivative and application thereof

The invention provides a crystal form of a neuroactive steroid derivative and application thereof, and belongs to the technical field of medicines. The crystal form of the neuroactive steroid derivative (with the structure as shown in the formula I) provided by the invention is radiated by Cu-K alpha, and characteristic diffraction peaks of an X-ray powder diffraction pattern expressed by a 2 theta angle comprise 11.450 + / -0.200 degrees, 15.724 + / -0.200 degrees, 19.040 + / -0.200 degrees, 22.955 + / -0.200 degrees and 24.975 + / -0.200 degrees. The crystal form provided by the invention has the advantages of good fluidity, no electrostatic phenomenon, high stability and almost no hygroscopicity, and can stably exist under the conditions of high temperature, high humidity and illumination; the compound has a relatively strong positive regulation effect on a GABAA receptor, has relatively good pharmacokinetic properties and oral absorption rate, and can be applied to preparation of oral and other dosage form medicines for efficiently resisting diseases such as postpartum depression. # imgabs0 #
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD

Phosphate or polymorphic form of imidazo [1, 2-a] pyridine compound

The invention provides a phosphate of a compound shown in a formula (I) and a polymorphic substance of the phosphate, and the phosphate and the polymorphic substance of the phosphate have excellent hygroscopicity, solubility and stability, have excellent druggability and are suitable for industrial production and storage. In addition, the phosphate and the polymorph thereof have excellent pharmacokinetic properties.
Owner:LIVZON PHARM GRP INC

Modified CAIX targeting cyclic peptide, nuclide marker and application of modified CAIX targeting cyclic peptide in tumor diagnosis and treatment

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.
Owner:WUHAN HEMING PHARMACEUTICAL TECHNOLOGY CO LTD

Tetrahydrofuroylamide compound as sodium channel regulator and application of tetrahydrofuroylamide compound in medicine

The invention provides an N-(hydroxyalkyl pyridyl) tetrahydrofuran carboxamide compound, a prodrug, an oxide, a salt, a metal complex or a stereochemical isomer of a sodium channel regulator and a pharmaceutical composition containing the N-(hydroxyalkyl pyridyl) tetrahydrofuran carboxamide compound, the prodrug, the oxide, the salt, the metal complex or the stereochemical isomer. And their use as Nav inhibitors and their use in the preparation of medicaments for the treatment and / or alleviation of pain and pain-related diseases. The compound provided by the invention has the advantages of high metabolic stability, high oral absorption, better bioavailability, better activity, higher selectivity, better pharmacokinetic property, quicker effect, low cardiac side effect and the like.
Owner:ANDIKANG (WUXI) BIOLOGICAL TECH CO LTD

Deuterated tetrahydrofuran NaV1.8 inhibitor and application thereof

The invention belongs to the field of medicine, and particularly discloses a deuterated tetrahydrofuran NaV1.8 inhibitor and application thereof, and the NaV1.8 inhibitor comprises a compound shown as a formula I or pharmaceutically acceptable salt and solvate thereof; wherein R1 and R2 are respectively and independently selected from H and deuterated C1-3 alkyl groups. The NaV1.8 inhibitor adopts a deuterated tetrahydrofuran medicine, the pharmacokinetic property of the NaV1.8 inhibitor can be remarkably improved, the administration dosage and toxic and side effects can be reduced, specifically, the channel activity IC50 of the NaV1.8 is lower than 0.1 nmol / L, the inhibitory activity IC50 of the NaV1.8 is lower than 43 nmol / L, the oral pharmacokinetic parameter t1 / 2 is 5.2 + / -1.2 h, and the NaV1.8 inhibitor is remarkably superior to a commercially available VX-548 preparation. # imgabs0 #
Owner:GUANGZHOU KEMROCMED CO LTD +1

Phenethylamine compounds salts, polymorphic forms and methods of use thereof

Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and / or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and / or a psychiatric disorder in a subject.
Owner:TERRAN BIOSCIENCES INC

PRMT5 inhibitor and preparation method therefor

The present invention relates to the field of medicine, and in particular to a PRMT5 inhibitor, as well as a preparation method therefor and a use thereof. The PRMT5 inhibitor is a compound as shown in formula (I), an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug, an isotope variant, or a pharmaceutically acceptable salt thereof. The present invention has better activity, selectivity, pharmacokinetic characteristics, safety or a wider treatment window.
Owner:BEIJING TIDE PHARMACEUTICAL CO LTD

Discovery method of cough-relieving and phlegm-eliminating quality marker of cough-relieving granules and quality marker

The invention relates to the technical field of traditional Chinese medicine research, in particular to a discovery method of a cough relieving and phlegm eliminating quality marker of cough relieving granules and the quality marker. According to the application, the cough-relieving and phlegm-eliminating drug effects of the cough-relieving granules are evaluated by virtue of concentrated ammonia water cough inducing and phenol red excretion tests, plasma pharmaceutical chemistry research of the cough-relieving granules is developed by virtue of a UHPLC-Q-Exactive Plus Orbitrap HRMS technology, and 26 prototype blood-entering components of the cough-relieving granules are analyzed and identified; through network pharmacological analysis of components entering blood, 11 potential active components for relieving cough and eliminating phlegm of the cough-relieving granules are screened, relate to 40 common targets such as IL6, TLR4, STAT3 and the like, and mainly participate in signal channels such as PI3K-Akt, HIF-1, EGFR (epidermal growth factor receptor) and the like; the seven prototype blood-entering components are quantitatively analyzed by utilizing pharmacokinetics. The three compounds of azelaic acid, caffeic acid and vanillin are used as the cough relieving and phlegm eliminating quality markers of the cough relieving granules through effectiveness, transitivity and testability. The research result is of great significance in deeply defining the pharmacodynamic material basis of the cough-relieving granules, optimizing the quality standard and promoting the clinical application of the cough-relieving granules.
Owner:GUIZHOU DALONG PHARM CO LTD